Asta Bio
February 10, 2025
Royale
Oncology
At Asta Bio, we are a targeted radiotherapy company harnessing the superior properties of alpha emitter 211-Astatine in combination with our proprietary multispecific Radiobodies™ that together deliver more powerful and precise radiation to the tumor while minimizing the harmful effects on normal cells. Our goal is to develop radiotherapies for breast, NSCLC, head and neck, ovarian, colorectal, GI, bladder cancers, and more. We were founded in July 2024 with investments from Indiebio and SOSV Ventures.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}